These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2192 related articles for article (PubMed ID: 27511158)

  • 1. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; Ludwig H; Chen W; Cavo M; Harousseau JL; Lentzsch S; Hillengass J; Palumbo A; Orfao A; Rajkumar SV; Miguel JS; Avet-Loiseau H
    Lancet Oncol; 2016 Aug; 17(8):e328-e346. PubMed ID: 27511158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
    Paiva B; Puig N; García-Sanz R; San Miguel JF;
    Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
    Landgren O; Rajkumar SV
    Clin Cancer Res; 2016 Nov; 22(22):5428-5433. PubMed ID: 28151710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
    Hillengass J; Usmani S; Rajkumar SV; Durie BGM; Mateos MV; Lonial S; Joao C; Anderson KC; García-Sanz R; Riva E; Du J; van de Donk N; Berdeja JG; Terpos E; Zamagni E; Kyle RA; San Miguel J; Goldschmidt H; Giralt S; Kumar S; Raje N; Ludwig H; Ocio E; Schots R; Einsele H; Schjesvold F; Chen WM; Abildgaard N; Lipe BC; Dytfeld D; Wirk BM; Drake M; Cavo M; Lahuerta JJ; Lentzsch S
    Lancet Oncol; 2019 Jun; 20(6):e302-e312. PubMed ID: 31162104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of multiple myeloma.
    Kumar L; Verma R; Radhakrishnan VR
    Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: disease response assessment.
    Zamagni E; Tacchetti P; Terragna C; Cavo M
    Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
    Gozzetti A; Bocchia M
    Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
    Mailankody S; Korde N; Lesokhin AM; Lendvai N; Hassoun H; Stetler-Stevenson M; Landgren O
    Nat Rev Clin Oncol; 2015 May; 12(5):286-95. PubMed ID: 25622976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
    Nishihori T; Song J; Shain KH
    Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep Response in Multiple Myeloma: A Critical Review.
    Fulciniti M; Munshi NC; Martinez-Lopez J
    Biomed Res Int; 2015; 2015():832049. PubMed ID: 26783530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardisation of minimal residual disease in multiple myeloma.
    Innao V; Allegra A; Russo S; Gerace D; Vaddinelli D; Alonci A; Allegra AG; Musolino C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28671297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.
    Teo WZY; Ong IYE; Tong JWY; Ong WL; Lin A; Song F; Tai BC; Ooi M; Seokojo CY; Chen Y; Nagarajan C; Chng WJ; de Mel S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):190-200. PubMed ID: 37400631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease monitoring in multiple myeloma.
    Davies FE; Rawstron AC; Owen RG; Morgan GJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari S; Hillengass J; McCarthy PL; Holstein SA
    Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
    Landgren O; Lu SX; Hultcrantz M
    Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
    Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
    Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.